Sunday, July 12, 2026
Peptide News NetworkPeer-reviewed science, translated for humans.
On July 23 and 24, an FDA advisory committee reviews seven peptides, including BPC-157, TB-500, and Semax, for the list that decides which substances pharmacists may legally compound.
Read the storyEvery headline drug in metabolic medicine is built from the same short list of hormones. Here is what each one does, and why companies keep combining them.
Parabilis Medicines' Nasdaq debut, priced at a $670 million offering and closing at $770.5 million, puts a stabilized-peptide platform atop a ranking long ruled by antibody and small-molecule firms.
The first single-molecule drug to combine GLP-1 and amylin activation showed meaningful glucose and weight effects in type 2 diabetes, an early signal of the field's move into amylin-based therapy.
The largest and longest trial yet of a drug that hits three gut-hormone receptors at once points to a new efficiency ceiling for obesity medicines, though these are topline results, not yet peer-reviewed.
The agency's proposed determination would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredient, unless a new shortage intervenes.
Not every peptide is studied to the same depth, and the distance between a compound with replicated clinical trials and one resting on a single animal paper is the whole story.
We sort every compound we cover into four tiers by the strength of its evidence and its regulatory standing, never by how popular or interesting it is. Many of the most talked-about research compounds sit in the lower tiers precisely because the human evidence is still thin. A tier is a reading aid, not a verdict.
Approved · specific indications
FDA-approved drugs with large, replicated clinical evidence. The research-grade material sold under these names is not the approved medicine.
Representative Tirzepatide · Tesamorelin · PT-141 · Oxytocin
Investigational or foreign / narrow approval
Real clinical evidence, often Phase 1–3, but not FDA-approved: still investigational, or cleared only abroad or for a single narrow use.
Representative Retatrutide · Cagrilintide · Thymosin Alpha-1 · SS-31
Not approved · research use only
Well characterized in cells and animals, with limited or no human outcome data. Several carry specific safety cautions of their own.
Representative BPC-157 · Ipamorelin · MOTS-c · GHK-Cu
Not approved · research use only
Early, narrow, or largely single-research-tradition evidence, with unresolved questions in places about a compound’s identity or sequence.
Representative Cardiogen · Pinealon · Vilon · Melanotan II
Each compound is described within the systems and populations actually studied: what the published literature and the regulatory record report, and nothing further. None of it is medical advice or a recommendation for use; unless noted, these compounds are sold for laboratory research only. The full research library is on its way.
A newsletter is on its way. Until it arrives, the feed is open — or send a note and we'll write to you when the first issue ships.
